Momenta Pharmaceuticals leverages its proprietary technology to unlock the structural secrets of complex sugars and other complex mixtures. Our unique tools and approach to drug development have yielded a diversified product pipeline consisting of both complex mixture generic and novel drugs.
Spotlight
Momenta Pharmaceuticals Reports
First Quarter 2012 Financial Results
- Phase 1/2 proof-of-concept trial for novel oncology drug candidate, M402, initiated; patient screening underway at trial sites in the U.S. -
CAMBRIDGE, MA — May 3, 2012 — Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the quarter ended March 31, 2012.
Read more here.
Momenta Featured in Nature Biotechnology!
Chinese Hamster Ovary Cells Can Produce Galactose-α-1,3-Galactose Antigens on Proteins
Read more about it here.
Congratulations to Momenta Pharmaceuticals President and CEO Craig Wheeler for receiving the Ernst & Young Entrepreneur Of The YearŽ 2011 New England Award in the Biotechnology category!
Click here to see the video